Zim Laboratories
Zim Laboratories Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Zim Laboratories Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Zim Laboratories Ltd trades at a P/E of 37.62× and P/B of 1.40×.
Valuation
Profitability
Growth
Financial Health
Zim Laboratories Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Zim Laboratories Ltd, switchable between annual and quarterly views, consolidated or standalone.
Zim Laboratories Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹610.97 Cr and reported EPS of ₹1.94.
| Period | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 335 | 278 | 307 | 333 | 399 | 367 | 379 | 374 |
| Other Income | 2 | 5 | 2 | 4 | 6 | 5 | 6 | 11 |
| Total Income | 337 | 282 | 310 | 338 | 405 | 373 | 385 | 386 |
| Cost of Goods Sold (COGS) | 160 | 143 | 159 | 160 | 199 | 171 | 168 | 165 |
| Gross Profit | 176 | 135 | 149 | 173 | 200 | 196 | 211 | 209 |
| +Operating Expenses | 134 | 112 | 109 | 132 | 148 | 155 | 167 | 179 |
| EBITDA | 42 | 23 | 40 | 41 | 52 | 41 | 44 | 30 |
| +Non-Operating Expenses | 22 | 27 | 22 | 24 | 23 | 23 | 32 | 33 |
| Profit Before Tax (PBT) | 22 | 0 | 10 | 21 | 35 | 24 | 18 | 8 |
| +Tax Expense | 7 | -3 | 3 | 6 | 11 | 6 | 6 | 2 |
| Profit After Tax (PAT) | 15 | 3 | 7 | 15 | 24 | 17 | 12 | 6 |
| Earnings Per Share (EPS) | 3.17 | 0.68 | 1.41 | 2.99 | 5.01 | 3.54 | 2.50 | 1.09 |
| Diluted Shares Outstanding (Nos.) | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| +Additional Disclosures | 475 | 426 | 452 | 478 | 569 | 520 | 535 | 545 |
| Sales Growth % | — | -17.18 | 10.63 | 8.52 | 19.52 | -7.80 | 3.16 | -1.22 |
| YoY Sales Growth % | — | -17.18 | 10.63 | 8.52 | 19.52 | -7.80 | 3.16 | -1.22 |
| Material Cost % | 43 | 48 | 50 | 48 | 41 | 48 | 41 | 44 |
| Employee Cost % | 14 | 18 | 12 | 12 | 12 | 15 | 16 | 17 |
| Other Cost % | 26 | 22 | 24 | 28 | 25 | 28 | 28 | 31 |
| OPM % | 13 | 8 | 13 | 12 | 13 | 11 | 12 | 8 |
| Tax % | 30 | -4,706 | 28 | 31 | 31 | 27 | 32 | 29 |
| Profit Growth % | — | -78.51 | 121.97 | 98.84 | 67.93 | -29.42 | -29.46 | -52.01 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 31 | 8 | 24 | 25 | 35 | 25 | 24 | 10 |
Zim Laboratories segment analysis: revenue and profit mix.
Disclosed business segments at Zim Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.
Zim Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Zim Laboratories Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Zim Laboratories Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Zim Laboratories Ltd's investment case rests on 8 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Healthy debt-to-equity ratio of 0.47 indicates conservative financial structure.
Diversified product portfolio across various oral dosage forms and therapeutic areas.
Established market presence with long history since 1984, domestically and internationally.
Price-to-book value of 1.37 suggests a reasonable valuation relative to assets.
Consistent 5-year revenue growth at 7.76% CAGR demonstrates business expansion.
What can break it.
Reported significant quarterly net loss of -1.87 Cr, a -308% decline.
Quarterly sales declined by -12.30%, indicating recent revenue contraction.
Low profitability with ROE at 4.96% and ROCE at 8.16%.
High P/E ratio of 42.90 suggests potential overvaluation given current earnings.
Negative EPS growth of -15.81% over the last five years.
What would change my mind.
Trim if P/E re-rates above 49. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Zim Laboratories Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Zim Laboratories Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Zim Laboratories Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Zim Laboratories Ltd — derived from the live tape, not yesterday's close.
Zim Laboratories Ltd last traded at ₹104.91 with an intraday range of ₹103.14–₹109.85 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹104.91| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 122.21 | +17.30 | +16.49% |
| R3 | 115.50 | +10.59 | +10.10% |
| R2 | 112.68 | +7.77 | +7.40% |
| R1 | 108.79 | +3.88 | +3.70% |
| PIVOT | 105.97 | 1.06 | 1.01% |
| CURRENT | 104.91 | — | — |
| S1 | 88.66 | -16.25 | -15.49% |
| S2 | 95.37 | -9.54 | -9.09% |
| S3 | 99.26 | -5.65 | -5.39% |
| S4 | 102.08 | -2.83 | -2.69% |
ZIMLAB is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ~
Trading Inside opening range
Zim Laboratories Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Zim Laboratories Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Zim Laboratories Ltd stood at 55.6% of traded volume, against a 20-day average of 57.8%.
Zim Laboratories announcements: results, concalls, ratings, M&A.
Filings Zim Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Zim Laboratories files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 84 documents below.
Copy of Newspaper Publication
Zim Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Copy of Newspaper Publication
Zim Laboratories Limited has informed the Exchange about Copy of Newspaper Publication-Corrigendum
Copy of Newspaper Publication
Zim Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Analysts/Institutional Investor Meet/Con. Call Updates
Zim Laboratories Limited has informed the Exchange about Transcript
Copy of Newspaper Publication
Zim Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
Zim Laboratories dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Zim Laboratories has declared, sequenced by announce and record date.
Zim Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Zim Laboratories Ltd: business, sector, key facts.
What Zim Laboratories Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Zim Laboratories Ltd operates in the Pharmaceuticals industry under the Health Care sector, listed as NSE: ZIMLAB, BSE: 541400.
ZIM Laboratories Limited is an Indian pharmaceutical company specializing in the development, manufacturing, and distribution of generic pharmaceutical and nutraceutical products. Their operations span both the domestic Indian market and international territories, establishing a significant presence in the global generic drug landscape. The company's long history, dating back to its incorporation in 1984, speaks to its experience and established position within the industry.
ZIMLAB's core business revolves around producing a wide range of pharmaceutical products in various oral solid dosage forms. This includes pre-formulation intermediates, which are essential components used in the creation of finished medications, and the finished formulations themselves. These finished products are diverse, encompassing pellets, taste-masked powders, granules, tablets, capsules, dry syrups, and oral thin films. This breadth of dosage forms allows ZIMLAB to cater to a large spectrum of patient needs and prescribing preferences.
The company's therapeutic focus is spread across several key areas of medicine. ZIMLAB offers products for urological conditions, gastroenterological issues, and infectious diseases (antibiotics and anti-infectives). They also produce medications addressing cardiovascular health, central nervous system disorders, pain (NSAIDs/pain analgesics), and provide a range of vitamins and supplements. This diversified portfolio helps to mitigate risks associated with reliance on a single therapeutic area and allows them to tap into multiple market segments.
Based in Nagpur, India, ZIMLAB's operations encompass the entire process from initial development and research to final manufacturing and distribution. Their established manufacturing capabilities, combined with a diversified product portfolio and focus on multiple therapeutic areas, position them as a significant player in the Indian and international pharmaceutical markets. The company’s longevity suggests a commitment to long-term growth and a consistent track record within a highly competitive industry.
Questions investors ask about Zim Laboratories Ltd (ZIMLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Zim Laboratories Ltd (ZIMLAB)?
The current share price of Zim Laboratories Ltd (ZIMLAB) is ₹104.91. Today, the stock has gained by ₹0.26 (0.25%), trading in a range of ₹103.14 to ₹109.85. The stock opened at ₹104.62 with a trading volume of 81,241 shares.
02Is Zim Laboratories Ltd stock a good investment for long-term?
Zim Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹610.97 crores, P/E ratio of 37.62, ROE of 2.94%, and ROCE of 8.16%. The dividend yield stands at 0.02%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Zim Laboratories Ltd stock?
The 52-week high price of Zim Laboratories Ltd (ZIMLAB) is ₹127, while the 52-week low is ₹59.31. Currently trading at ₹104.91, the stock is 67.4% away from its 52-week low and 17.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Zim Laboratories Ltd stock at the current price?
Whether to buy Zim Laboratories Ltd stock at ₹104.91 depends on multiple factors. The stock is currently trading with a P/E ratio of 37.62 and P/B ratio of 1.40. Today's performance shows a gain of 0.25%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Zim Laboratories Ltd and when is the next dividend?
Zim Laboratories Ltd offers a dividend yield of 0.02%, which means for every ₹100 invested at the current price of ₹104.91, you can expect to receive approximately ₹0.02 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Zim Laboratories Ltd?
Zim Laboratories Ltd's key financial metrics include: P/E Ratio: 37.62, P/B Ratio: 1.40, ROE: 2.94%, ROCE: 8.16%, Dividend Yield: 0.02%, EPS: ₹1.94, Book Value: ₹51.77, and Debt-to-Equity: 0.47. The company's market cap stands at ₹610.97 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Zim Laboratories Ltd stock performing today in the market?
Zim Laboratories Ltd stock opened at ₹104.62 and is currently trading at ₹104.91, showing a gain of ₹0.26 (0.25%). The intraday high is ₹109.85 and low is ₹103.14. The trading volume stands at 81,241 shares, indicating moderate market participation today.
08What is the P/E ratio of Zim Laboratories Ltd and what does it indicate?
Zim Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 37.62, which means investors are willing to pay ₹37.62 for every ₹1 of earnings. With an EPS of ₹1.94, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Zim Laboratories Ltd (ZIMLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy